Deep characterization of blood cell miRNomes by NGS

A systematic understanding of different factors influencing cell type specific microRNA profiles is essential for state-of-the art biomarker research. We carried out a comprehensive analysis of the biological variability and changes in cell type pattern over time for different cell types and different isolation approaches in technical replicates. All combinations of the parameters mentioned above have been measured, resulting in 108 miRNA profiles that were evaluated by next-generation-sequencing. The largest miRNA variability was due to inter-individual differences (34 %), followed by the cell types (23.4 %) and the isolation technique (17.2 %). The change over time in cell miRNA composition was moderate (<3 %) being close to the technical variations (<1 %). Largest variability (including technical and biological variance) was observed for CD8 cells while CD3 and CD4 cells showed significantly lower variations. ANOVA highlighted that 51.5 % of all miRNAs were significantly influenced by the purification technique. While CD4 cells were least affected, especially miRNA profiles of CD8 cells were fluctuating depending on the cell purification approach. To provide researchers access to the profiles and to allow further analyses of the tested conditions we implemented a dynamic web resource.

[1]  Christina Backes,et al.  Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing , 2014, Multiple sclerosis.

[2]  K. Witwer,et al.  OpenArray profiling reveals no differential modulation of miRNA by positive and negative CD4+ T cell immunoselection. , 2014, Experimental hematology.

[3]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[4]  Hans-Peter Lenhof,et al.  Multiple Sclerosis: MicroRNA Expression Profiles Accurately Differentiate Patients with Relapsing-Remitting Disease from Healthy Controls , 2009, PloS one.

[5]  Sebastian D. Mackowiak,et al.  miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades , 2011, Nucleic acids research.

[6]  R. Stahel,et al.  Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). , 2014, Lung cancer.

[7]  Christina Backes,et al.  The human miRNA repertoire of different blood compounds , 2014, BMC Genomics.

[8]  Hugo A. Katus,et al.  MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction , 2010, Basic Research in Cardiology.

[9]  Kenneth G. C. Smith,et al.  Microarray analysis of human leucocyte subsets: the advantages of positive selection and rapid purification , 2007, BMC Genomics.

[10]  J. Haas,et al.  Prioritizing and selecting likely novel miRNAs from NGS data , 2015, Nucleic acids research.

[11]  F. Zufall,et al.  A simple, economic, time‐resolved killing assay , 2014, European journal of immunology.

[12]  Sabine C. Mueller,et al.  A blood based 12-miRNA signature of Alzheimer disease patients , 2013, Genome Biology.

[13]  Christina Backes,et al.  What makes a blood cell based miRNA expression pattern disease specific? - A miRNome analysis of blood cell subsets in lung cancer patients and healthy controls , 2014, Oncotarget.

[14]  C. Spina,et al.  The effect of cell subset isolation method on gene expression in leukocytes , 2014, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[15]  The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases , 2014, Molecular Cancer.

[16]  Stijn van Dongen,et al.  miRBase: microRNA sequences, targets and gene nomenclature , 2005, Nucleic Acids Res..

[17]  C. Croce,et al.  MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. , 2007, JAMA.

[18]  Christina Backes,et al.  Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. , 2015, European journal of cancer.